Table 3 Numbers of OROS-MPH dose titration and the corresponding index episode duration, by age groups
| Â | United States | Japan | ||
|---|---|---|---|---|
Child group (n = 98,973) | Adolescent group (n = 62,002) | Child group (n = 4595) | Adolescent group (n = 1508) | |
Number of dose titration, n (%) | ||||
 0 | 68,736 (69.4) | 50,637 (81.7) | 2955 (64.3) | 930 (61.7) |
  ≥ 1 | 30,237 (30.6) | 11,365 (18.3) | 1640 (35.7) | 578 (38.3) |
   1 | 13,589 (13.7) | 6045 (9.7) | 664 (14.5) | 242 (16.0) |
   2 | 7294 (7.4) | 2667 (4.3) | 336 (7.3) | 130 (8.6) |
    ≥ 3 | 9354 (9.5) | 2653 (4.3) | 640 (13.9) | 206 (13.7) |
Median duration of the index episode, months (IQR) | ||||
 Patients with 0 dose titration | 5.4 (1.0–15.0) | 4.8 (1.0–13.4) | 7.5 (1.0–21.0) | 3.0 (1.0–13.9) |
 Patients with 1 dose titration | 16.4 (8.5–27.3) | 13.0 (6.2–21.9) | 20.2 (8.8–34.8) | 15.3 (5.4–25.5) |
 Patients with 2 dose titrations | 20.6 (12.4–33.2) | 16.2 (9.3–26.3) | 26.2 (14.0–45.4) | 15.7 (7.8–23.4) |
 Patients with ≥3 dose titrations | 28.7 (16.9–46.3) | 23.0 (14.0–34.4) | 34.2 (18.9–54.5) | 23.1 (14.1–37.3) |